{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:15:55Z","timestamp":1791875755542,"version":"4.3.4"},"reference-count":127,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T00:00:00Z","timestamp":1613001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>There is considerable experimental evidence that the renin angiotensin system (RAS) plays a central role in both hepatic fibrogenesis and portal hypertension. Angiotensin converting enzyme (ACE), a key enzyme of the classical RAS, converts angiotensin I (Ang I) to angiotensin II (Ang II), which acts via the Ang II type 1 receptor (AT1R) to stimulate hepatic fibrosis and increase intrahepatic vascular tone and portal pressure. Inhibitors of the classical RAS, drugs which are widely used in clinical practice in patients with hypertension, have been shown to inhibit liver fibrosis in animal models but their efficacy in human liver disease is yet to be tested in adequately powered clinical trials. Small trials in cirrhotic patients have demonstrated that these drugs may lower portal pressure but produce off-target complications such as systemic hypotension and renal failure. More recently, the alternate RAS, comprising its key enzyme, ACE2, the effector peptide angiotensin-(1\u20137) (Ang-(1\u20137)) which mediates its effects via the putative receptor Mas (MasR), has also been implicated in the pathogenesis of liver fibrosis and portal hypertension. This system is activated in both preclinical animal models and human chronic liver disease and it is now well established that the alternate RAS counter-regulates many of the deleterious effects of the ACE-dependent classical RAS. Work from our laboratory has demonstrated that liver-specific ACE2 overexpression reduces hepatic fibrosis and liver perfusion pressure without producing off-target effects. In addition, recent studies suggest that the blockers of the receptors of alternate RAS, such as the MasR and Mas related G protein-coupled receptor type-D (MrgD), increase splanchnic vascular resistance in cirrhotic animals, and thus drugs targeting the alternate RAS may be useful in the treatment of portal hypertension. This review outlines the role of the RAS in liver fibrosis and portal hypertension with a special emphasis on the possible new therapeutic approaches targeting the ACE2-driven alternate RAS.<\/jats:p>","DOI":"10.3390\/jcm10040702","type":"journal-article","created":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T16:12:10Z","timestamp":1613146330000},"page":"702","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Update on New Aspects of the Renin-Angiotensin System in Hepatic Fibrosis and Portal Hypertension: Implications for Novel Therapeutic Options"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3326-3654","authenticated-orcid":false,"given":"Indu G.","family":"Rajapaksha","sequence":"first","affiliation":[{"name":"Department of Medicine, The University of Melbourne, Austin Health, Heidelberg, VIC 3084, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5841-057X","authenticated-orcid":false,"given":"Lakmie S.","family":"Gunarathne","sequence":"additional","affiliation":[{"name":"Department of Medicine, The University of Melbourne, Austin Health, Heidelberg, VIC 3084, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W.","family":"Angus","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Austin Health, Melbourne, VIC 3084, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandana B.","family":"Herath","sequence":"additional","affiliation":[{"name":"Department of Medicine, The University of Melbourne, Austin Health, Heidelberg, VIC 3084, Australia"},{"name":"South Western Sydney Clinical School, Faculty of Medicine, Ingham Institute for Applied Medical Research, University of New South Wales, Liverpool, NSW 2170, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1053\/j.gastro.2008.03.003","article-title":"Mechanisms of hepatic fibrogenesis","volume":"134","author":"Friedman","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(08)60383-9","article-title":"Liver cirrhosis","volume":"371","author":"Schuppan","year":"2008","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1042\/CS20120030","article-title":"Update on new aspects of the renin\u2013angiotensin system in liver disease: Clinical implications and new therapeutic options","volume":"123","author":"Grace","year":"2012","journal-title":"Clin. Sci."},{"key":"ref_4","unstructured":"WHO (2019). Summary Tables of Mortality Estimates by Cause, Age and Sex, Globally and by Region, 2000\u20132016, WHO."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"7312","DOI":"10.3748\/wjg.v20.i23.7312","article-title":"Pathogenesis of liver cirrhosis","volume":"20","author":"Zhou","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4291\/wjgp.v10.i1.1","article-title":"Current therapies and novel approaches for biliary diseases","volume":"10","author":"Rajapaksha","year":"2019","journal-title":"World J. Gastrointest. Pathophysiol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Berzigotti, A. (2017). Advances and challenges in cirrhosis and portal hypertension. BMC Med., 15.","DOI":"10.1186\/s12916-017-0966-6"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1042\/CS20070026","article-title":"Liver fibrosis: A balance of ACEs?","volume":"113","author":"Warner","year":"2007","journal-title":"Clin. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/j.1440-1746.2008.05461.x","article-title":"Liver disease and the renin-angiotensin system: Recent discoveries and clinical implications","volume":"23","author":"Lubel","year":"2008","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Sanso\u00e8, G., Aragno, M., Mastrocola, R., Mengozzi, G., Novo, E., and Parola, M. (2016). Role of Chymase in the Development of Liver Cirrhosis and Its Complications: Experimental and Human Data. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0162644"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/j.1872-034X.2010.00672.x","article-title":"Chymase inhibition attenuates tetrachloride-induced liver fibrosis in hamsters","volume":"40","author":"Komeda","year":"2010","journal-title":"Hepatol. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.coph.2010.11.002","article-title":"Non-peptide AT2-receptor agonists","volume":"11","author":"Steckelings","year":"2011","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.peptides.2014.10.005","article-title":"The role of renin-angiotensin system modulation on treatment and prevention of liver diseases","volume":"62","author":"Feltenberger","year":"2014","journal-title":"Peptides"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1161\/01.CIR.0000141736.76561.78","article-title":"Renin-Angiotensin System and Angiotensin Receptor Blockers in the Metabolic Syndrome","volume":"110","author":"Prasad","year":"2004","journal-title":"Circulation"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/01.RES.87.5.e1","article-title":"A Novel Angiotensin-Converting Enzyme\u2013Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9","volume":"87","author":"Donoghue","year":"2000","journal-title":"Circ. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"33238","DOI":"10.1074\/jbc.M002615200","article-title":"A Human Homolog of Angiotensin-converting Enzyme: Cloning and Functional Expression as a Captopril-Insensitive Carboxypeptidase","volume":"275","author":"Tipnis","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1073\/pnas.85.11.4095","article-title":"Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(1\u20137) heptapeptide","volume":"85","author":"Schiavone","year":"1988","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Chappell, M.C. (2019). The Angiotensin-(1\u20137) Axis: Formation and Metabolism Pathways. Angiotensin-(1\u20137), 1\u201326.","DOI":"10.1007\/978-3-030-22696-1_1"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"8258","DOI":"10.1073\/pnas.1432869100","article-title":"Angiotensin-(1\u20137) is an endogenous ligand for the G protein-coupled receptor Mas","volume":"100","author":"Santos","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1161\/01.HYP.0000052947.60363.24","article-title":"Characterization of a New Selective Antagonist for Angiotensin-(1\u20137), d-Pro7-Angiotensin-(1\u20137)","volume":"41","author":"Santos","year":"2003","journal-title":"Hypertension"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.peptides.2006.10.007","article-title":"Evidence for a new angiotensin-(1\u20137) receptor subtype in the aorta of Sprague\u2013Dawley rats","volume":"28","author":"Silva","year":"2007","journal-title":"Peptides"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11010-008-9884-4","article-title":"Angiotensin metabolites can stimulate receptors of the Mas-related genes family","volume":"319","author":"Gembardt","year":"2008","journal-title":"Mol. Cell. Biochem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCRESAHA.113.301077","article-title":"Discovery and characterization of alamandine: A novel component of the renin-angiotensin system","volume":"112","author":"Lautner","year":"2013","journal-title":"Circ. Res."},{"key":"ref_24","first-page":"G99","article-title":"Angiotensin-(1\u20137) reduces the perfusion pressure response to angiotensin II and methoxamine via an endothelial nitric oxide-mediated pathway in cirrhotic rat liver","volume":"304","author":"Herath","year":"2013","journal-title":"Am. J. Physiol. Liver Physiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1161\/HYPERTENSIONAHA.116.07572","article-title":"G-Protein\u2013Coupled Receptor MrgD Is a Receptor for Angiotensin-(1\u20137) Involving Adenylyl Cyclase, cAMP, and Phosphokinase","volume":"68","author":"Tetzner","year":"2016","journal-title":"Hypertension"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1146\/annurev.pharmtox.010909.105610","article-title":"Tissue Renin-Angiotensin-Aldosterone Systems: Targets for Pharmacological Therapy","volume":"50","author":"Bader","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Nehme, A., Zouein, F.A., Zayeri, Z.D., and Zibara, K. (2019). An Update on the Tissue Renin Angiotensin System and Its Role in Physiology and Pathology. J. Cardiovasc. Dev. Dis., 6.","DOI":"10.3390\/jcdd6020014"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0016-5085(03)00695-4","article-title":"Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II","volume":"125","author":"Bataller","year":"2003","journal-title":"Gastroenterology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrcardio.2012.196","article-title":"Targeting the renin-angiotensin-aldosterone system in heart failure","volume":"10","author":"Lang","year":"2013","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.trsl.2008.12.008","article-title":"Renin-angiotensin-aldosterone system-mediated redox effects in chronic kidney disease","volume":"153","author":"Nistala","year":"2009","journal-title":"Transl. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1172\/JCI18212","article-title":"NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis","volume":"112","author":"Bataller","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1042\/CS20080647","article-title":"Angiotensin-(1\u20137), an alternative metabolite of the renin\u2013angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat","volume":"117","author":"Lubel","year":"2009","journal-title":"Clin. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1053\/gast.2002.36561","article-title":"Up-regulation of components of the renin-angiotensin system in the bile duct\u2013ligated rat liver","volume":"123","author":"Paizis","year":"2002","journal-title":"Gastroenterology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1152\/physrev.00036.2005","article-title":"Physiology of Local Renin-Angiotensin Systems","volume":"86","author":"Paul","year":"2006","journal-title":"Physiol. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jhep.2007.03.008","article-title":"Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1\u20137) levels in experimental biliary fibrosis","volume":"47","author":"Herath","year":"2007","journal-title":"J. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/mt.2015.92","article-title":"ACE2 Therapy Using Adeno-associated Viral Vector Inhibits Liver Fibrosis in Mice","volume":"23","author":"Mak","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-28490-y","article-title":"The small molecule drug diminazene aceturate inhibits liver injury and biliary fibrosis in mice","volume":"8","author":"Rajapaksha","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1152\/physrev.00013.2007","article-title":"Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver","volume":"88","author":"Friedman","year":"2008","journal-title":"Physiol. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1002\/hep.20665","article-title":"Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats","volume":"41","author":"Bataller","year":"2005","journal-title":"Hepatology"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Herath, C.B., Mak, K.Y., and Angus, P.W. (2015). Role of the Alternate RAS in Liver Disease and the GI Tract. The Protective Arm of the Renin Angiotensin System (RAS), Elsevier.","DOI":"10.1016\/B978-0-12-801364-9.00034-1"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0016-5085(00)70368-4","article-title":"Angiotensin II induces contraction and proliferation of human hepatic stellate cells","volume":"118","author":"Bataller","year":"2000","journal-title":"Gastroenterology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/hep.27376","article-title":"Liver sinusoidal endothelial cells in hepatic fibrosis","volume":"61","author":"Deleve","year":"2015","journal-title":"Hepatology"},{"key":"ref_43","unstructured":"Maretti-Mira, A.C., Wang, X., Wang, L., and DeLeve, L.D. (2016). Role of incomplete stem cell maturation in hepatic fibrosis. HEPATOLOGY, Wiley-Blackwell."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1083\/jcb.127.6.2037","article-title":"Expression of variant fibronectins in wound healing: Cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis","volume":"127","author":"Jarnagin","year":"1994","journal-title":"J. Cell Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jhep.2016.04.018","article-title":"Sinusoidal communication in liver fibrosis and regeneration","volume":"65","author":"Marrone","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1053\/gast.2001.25480","article-title":"Angiotensin-Converting Enzyme Inhibition Attenuates the Progression of Rat Hepatic Fibrosis","volume":"121","author":"Jonsson","year":"2001","journal-title":"Gastroenterology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s10620-007-9941-y","article-title":"Effect of Angiotensin-converting Enzyme Inhibition on Experimental Hepatic Fibrogenesis","volume":"53","author":"Turkay","year":"2007","journal-title":"Dig. Dis. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0168-8278(01)00146-5","article-title":"Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis","volume":"35","author":"Paizis","year":"2001","journal-title":"J. Hepatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1038\/aps.2012.115","article-title":"Telmisartan attenuates hepatic fibrosis in bile duct-ligated rats","volume":"33","author":"Yi","year":"2012","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"540","DOI":"10.3748\/wjg.v6.i6.824","article-title":"Effects of AT1 receptor antagonist, losartan, on rat hepatic fibrosis induced by CCl4","volume":"6","author":"Wei","year":"2000","journal-title":"World J. Gastroenterol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/hep.21638","article-title":"Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis","volume":"45","author":"Hirose","year":"2007","journal-title":"Hepatology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1478-3231.2009.01973.x","article-title":"The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C","volume":"29","author":"Corey","year":"2009","journal-title":"Liver Int."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/bcpt.12844","article-title":"Statins and Angiotensin-Converting Enzyme Inhibitors are Associated with Reduced Mortality and Morbidity in Chronic Liver Disease","volume":"122","author":"Stokkeland","year":"2018","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1478-3231.2012.02774.x","article-title":"Beneficial effects of candesartan, an angiotensin-blocking agent, on compensated alcoholic liver fibrosis\u2014A randomized open-label controlled study","volume":"32","author":"Kim","year":"2012","journal-title":"Liver Int."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1007\/s00535-011-0449-z","article-title":"Effects of 1-year administration of olmesartan on portal pressure and TGF-beta1 in selected patients with cirrhosis: A randomized controlled trial","volume":"46","author":"Hidaka","year":"2011","journal-title":"J. Gastroenterol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jhep.2007.01.017","article-title":"AT1 receptor antagonist Candesartan in selected cirrhotic patients: Effect on portal pressure and liver fibrosis markers","volume":"46","author":"Martini","year":"2007","journal-title":"J. Hepatol."},{"key":"ref_57","first-page":"539","article-title":"Combination of branched-chain amino acid and angiotensin-converting enzyme inhibitor improves liver fibrosis progression in patients with cirrhosis","volume":"5","author":"Yoshiji","year":"2011","journal-title":"Mol. Med. Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1053\/jhep.2002.32679","article-title":"Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C","volume":"36","author":"Terui","year":"2002","journal-title":"Hepatology"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"McPherson, S., Wilkinson, N., Tiniakos, D., Wilkinson, J., Burt, A.D., McColl, E., Stocken, D.D., Steen, N., Barnes, J., and Goudie, N. (2017). A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0175717"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Zhu, Q., Li, N., Li, F., Zhou, Z., Han, Q., Lv, Y., Sang, J., and Liu, Z. (2016). Therapeutic effect of renin angiotensin system inhibitors on liver fibrosis. J. Renin-Angiotensin-Aldosterone Syst., 17.","DOI":"10.1177\/1470320316628717"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/hep.26359","article-title":"Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012","volume":"57","author":"Runyon","year":"2013","journal-title":"Hepatology"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"EASL (2018). EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J. Hepatol., 69, 406\u2013460.","DOI":"10.1016\/j.jhep.2018.03.024"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1136\/gut.2004.062398","article-title":"Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2","volume":"54","author":"Paizis","year":"2005","journal-title":"Gut"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/hep4.1434","article-title":"Liver-Targeted Angiotensin Converting Enzyme 2 Therapy Inhibits Chronic Biliary Fibrosis in Multiple Drug-Resistant Gene 2-Knockout Mice","volume":"3","author":"Rajapaksha","year":"2019","journal-title":"Hepatol. Commun."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1161\/HYPERTENSIONAHA.110.167346","article-title":"An Oral Formulation of Angiotensin-(1\u20137) Produces Cardioprotective Effects in Infarcted and Isoproterenol-Treated Rats","volume":"57","author":"Marques","year":"2011","journal-title":"Hypertension"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"151893","DOI":"10.1016\/j.imbio.2019.12.002","article-title":"Oral formulation angiotensin-(1\u20137) therapy attenuates pulmonary and systemic damage in mice with emphysema induced by elastase","volume":"225","author":"Bastos","year":"2020","journal-title":"Immunobiology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/5868935","article-title":"Antioxidant Effects of Oral Ang-(1\u20137) Restore Insulin Pathway and RAS Components Ameliorating Cardiometabolic Disturbances in Rats","volume":"2019","author":"Figueiredo","year":"2019","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/HYPERTENSIONAHA.109.138420","article-title":"Targeting the Degradation of Angiotensin II With Recombinant Angiotensin-Converting Enzyme 2","volume":"55","author":"Wysocki","year":"2010","journal-title":"Hypertension"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2337\/db09-1218","article-title":"Human Recombinant ACE2 Reduces the Progression of Diabetic Nephropathy","volume":"59","author":"Oudit","year":"2009","journal-title":"Diabetes"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40262-013-0072-7","article-title":"Pharmacokinetics and Pharmacodynamics of Recombinant Human Angiotensin-Converting Enzyme 2 in Healthy Human Subjects","volume":"52","author":"Haschke","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/hep.23104","article-title":"Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice","volume":"50","author":"Taura","year":"2009","journal-title":"Hepatology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-Associated Virus (AAV) as a Vector for Gene Therapy","volume":"31","author":"Naso","year":"2017","journal-title":"BioDrugs"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/gt.2008.64","article-title":"Potential of AAV vectors in the treatment of metabolic disease","volume":"15","author":"Alexander","year":"2008","journal-title":"Gene Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1161\/HYPERTENSIONAHA.107.108944","article-title":"Structure-Based Identification of Small-Molecule Angiotensin-Converting Enzyme 2 Activators as Novel Antihypertensive Agents","volume":"51","author":"Prada","year":"2008","journal-title":"Hypertension"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2119\/molmed.2009.00160","article-title":"ACE2 Activation Promotes Antithrombotic Activity","volume":"16","author":"Sorg","year":"2010","journal-title":"Mol. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.reprotox.2014.08.006","article-title":"ACE2 activation by xanthenone prevents leptin-induced increases in blood pressure and proteinuria during pregnancy in Sprague-Dawley rats","volume":"49","author":"Ibrahim","year":"2014","journal-title":"Reprod. Toxicol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1113\/expphysiol.2010.055277","article-title":"Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases","volume":"96","author":"Ferreira","year":"2011","journal-title":"Exp. Physiol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00210-018-1523-3","article-title":"Modulation of brain ACE and ACE2 may be a promising protective strategy against cerebral ischemia\/reperfusion injury: An experimental trial in rats","volume":"391","author":"Messiha","year":"2018","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1161\/HYPERTENSIONAHA.113.01337","article-title":"Diminazene Aceturate Enhances Angiotensin-Converting Enzyme 2 Activity and Attenuates Ischemia-Induced Cardiac Pathophysiology","volume":"62","author":"Qi","year":"2013","journal-title":"Hypertension"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1164\/rccm.201205-0880OC","article-title":"Diminazene Attenuates Pulmonary Hypertension and Improves Angiogenic Progenitor Cell Functions in Experimental Models","volume":"187","author":"Shenoy","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0001-706X(93)90092-P","article-title":"Pharmacology of diminazene: A review","volume":"54","author":"Peregrine","year":"1993","journal-title":"Acta Trop."},{"key":"ref_82","first-page":"148","article-title":"Retrospective long-term study of effects of berenil by follow-up of patients treated since 1965","volume":"35","author":"Abaru","year":"1984","journal-title":"Tropenmedizin und Parasitol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1167\/iovs.14-13883","article-title":"Angiotensin-Converting Enzyme 2 (ACE2) Activator Diminazene Aceturate Ameliorates Endotoxin-Induced Uveitis in Mice","volume":"55","author":"Qiu","year":"2014","journal-title":"Investig. Opthalmology Vis. Sci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.1167\/iovs.12-11427","article-title":"Antiglaucomatous Effects of the Activation of Intrinsic Angiotensin-Converting Enzyme 2","volume":"54","author":"Foureaux","year":"2013","journal-title":"Investig. Opthalmology Vis. Sci."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-016-0489-7","article-title":"Angiotensin-converting enzyme 2 activator diminazene aceturate prevents lipopolysaccharide-induced inflammation by inhibiting MAPK and NF-\u039aB pathways in human retinal pigment epithelium","volume":"13","author":"Tao","year":"2016","journal-title":"J. Neuroinflamm."},{"key":"ref_86","first-page":"141","article-title":"Complications of cirrhosis","volume":"32","author":"Bosch","year":"2000","journal-title":"I. Portal hypertension. J. Hepatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.cgh.2006.09.009","article-title":"Portal Hypertension and Hepatocellular Carcinoma: Prognosis and Beyond","volume":"4","author":"Tandon","year":"2006","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_88","unstructured":"Abraldes, J.G., Bosch, J., and Abralde\u1e63, J.G. (2007). Clinical Features and Natural History of Variceal Hemorrhage. Clinical Gastroenterology, Springer Nature."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2007.05.024","article-title":"Hepatic Venous Pressure Gradient Predicts Clinical Decompensation in Patients With Compensated Cirrhosis","volume":"133","author":"Ripoll","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"208","DOI":"10.4254\/wjh.v2.i6.208","article-title":"Physiopathology of splanchnic vasodilation in portal hypertension","volume":"2","author":"Martell","year":"2010","journal-title":"World J. Hepatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1097\/01.mcg.0000155552.14396.3d","article-title":"Portal hypertension: From bedside to bench","volume":"39","author":"Groszmann","year":"2005","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0016-5085(01)81028-3","article-title":"Isosorbide Mononitrate in the Prevention of First Variceal Bleed in Patients Who Cannot Receive \u03b2-blockers","volume":"121","author":"Villanueva","year":"2001","journal-title":"Gastroenterology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jhep.2013.09.016","article-title":"The changing role of beta-blocker therapy in patients with cirrhosis","volume":"60","author":"Ge","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_94","first-page":"332","article-title":"The treatment of portal hypertension: A meta-analytic review","volume":"22","author":"Pagliaro","year":"1995","journal-title":"Hepatology"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jhep.2010.03.013","article-title":"Renin\u2013angiotensin\u2013aldosterone inhibitors in the reduction of portal pressure: A systematic review and meta-analysis","volume":"53","author":"Tandon","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1136\/gut.2007.144584","article-title":"Mechanisms of extrahepatic vasodilation in portal hypertension","volume":"57","author":"Hennenberg","year":"2008","journal-title":"Gut"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1872-034X.2009.00581.x","article-title":"Role of angiotensin II in liver fibrosis-induced portal hypertension and therapeutic implications","volume":"40","year":"2010","journal-title":"Hepatol. Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.3748\/wjg.v23.i19.3396","article-title":"Renin angiotensin system in liver diseases: Friend or foe?","volume":"23","author":"Silva","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1053\/j.gastro.2013.06.036","article-title":"Activation of the Mas Receptor by Angiotensin-(1\u20137) in the Renin\u2013Angiotensin System Mediates Mesenteric Vasodilatation in Cirrhosis","volume":"145","author":"Grace","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.3389\/fphys.2019.01169","article-title":"Blockade of Mas Receptor or Mas-Related G-Protein Coupled Receptor Type D Reduces Portal Pressure in Cirrhotic but Not in Non-cirrhotic Portal Hypertensive Rats","volume":"10","author":"Gunarathne","year":"2019","journal-title":"Front. Physiol."},{"key":"ref_101","first-page":"G98","article-title":"Portal pressure responses and angiotensin peptide production in rat liver are determined by relative activity of ACE and ACE2","volume":"297","author":"Herath","year":"2009","journal-title":"Am. J. Physiol. Liver Physiol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.3748\/wjg.v26.i40.6111","article-title":"Cirrhotic portal hypertension: From pathophysiology to novel therapeutics","volume":"26","author":"Gunarathne","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0168-8278(02)00104-6","article-title":"Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats","volume":"37","author":"Yoshiji","year":"2002","journal-title":"J. Hepatol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"824","DOI":"10.3748\/wjg.v6.i6.824","article-title":"The regulatory role of AT1 receptor on activated HSCs in hepatic fibrogenesis: Effects of RAS inhibitors on hepatic fibrosis induced by CCl4","volume":"6","author":"Wei","year":"2000","journal-title":"World J. Gastroenterol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1365-2362.1991.tb01816.x","article-title":"Plasma noradrenaline in cirrhosis: A study of kinetics and temporal relationship to ascites formation","volume":"21","author":"Macgilchrist","year":"1991","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1097\/01.CCM.0000178173.27923.EB","article-title":"Vasoconstrictor hyporeactivity can be reversed by antioxidants in patients with advanced alcoholic cirrhosis of the liver and ascites","volume":"33","author":"Ferlitsch","year":"2005","journal-title":"Crit. Care Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1136\/gut.2005.088633","article-title":"Role of endothelin in systemic and portal resistance in cirrhosis","volume":"55","author":"Angus","year":"2006","journal-title":"Gut"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.gtc.2010.08.015","article-title":"Clinical Pharmacology of Portal Hypertension","volume":"39","year":"2010","journal-title":"Gastroenterol. Clin. North Am."},{"key":"ref_109","first-page":"G996","article-title":"In vitro hyporeactivity to methoxamine in portal hypertensive rats: Reversal by nitric oxide blockade","volume":"262","author":"Sieber","year":"1992","journal-title":"Am. J. Physiol. Liver Physiol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0008-6363(98)00008-X","article-title":"Peripheral vascular tone in patients with cirrhosis: Role of the renin\u2013angiotensin and sympathetic nervous systems","volume":"38","author":"Newby","year":"1998","journal-title":"Cardiovasc. Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/hep.21502","article-title":"Vascular dysfunction in human and rat cirrhosis: Role of receptor-desensitizing and calcium-sensitizing proteins","volume":"45","author":"Hennenberg","year":"2007","journal-title":"Hepatology"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1365-2362.2003.01131.x","article-title":"Portal hypertension is associated with increased mRNA levels of vasopressor G-protein-coupled receptors in human hepatic arteries","volume":"33","author":"Neef","year":"2003","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1053\/j.gastro.2005.11.029","article-title":"Defective RhoA\/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats","volume":"130","author":"Hennenberg","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/j.1365-2362.2009.02181.x","article-title":"Vascular hyporesponsiveness to angiotensin II in rats with CCl4-induced liver cirrhosis","volume":"39","author":"Hennenberg","year":"2009","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.3748\/wjg.15.2512","article-title":"Relationship between angiotensin-(1\u20137) and angiotensin II correlates with hemodynamic changes in human liver cirrhosis","volume":"15","author":"Pereira","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0006-2952(97)00039-7","article-title":"Hyperpolarizing Factors","volume":"54","author":"Quilley","year":"1997","journal-title":"Biochem. Pharmacol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1098-8823(03)00077-7","article-title":"Role of cytochrome P450-dependent arachidonic acid metabolites in liver physiology and pathophysiology","volume":"72","author":"Sacerdoti","year":"2003","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.2174\/092986706779026138","article-title":"Impact of inhibitors of the Renin-Angiotensin-aldosterone system on liver fibrosis and portal hypertension","volume":"13","author":"Tox","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/0002-9343(84)90887-8","article-title":"Effects of captopril on hepatic venous pressure and blood flow in patients with liver cirrhosis","volume":"76","author":"Eriksson","year":"1984","journal-title":"Am. J. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1007\/s00535-003-1222-8","article-title":"Captopril reduces portal pressure effectively in portal hypertensive patients with low portal venous velocity","volume":"38","author":"Baik","year":"2003","journal-title":"J. Gastroenterol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1440-1746.1995.tb01090.x","article-title":"Haemodynamic effects of enalaprilat on portal hypertension in patients with HBsAg-positive cirrhosis","volume":"10","author":"Chiang","year":"1995","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_122","first-page":"124","article-title":"Effect of enalapril treatment and sclerotherapy of esophageal varices on hepatic hemodynamics in portal hypertension","volume":"39","author":"Svoboda","year":"1992","journal-title":"Hepatogastroenterology"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jhep.2007.03.014","article-title":"Enhanced vasoconstrictor prostanoid production by sinusoidal endothelial cells increases portal perfusion pressure in cirrhotic rat livers","volume":"47","author":"Bosch","year":"2007","journal-title":"J. Hepatol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/j.1572-0241.2007.01759.x","article-title":"Irbesartan Plus Low-Dose Propranolol Versus Low-Dose Propranolol Alone in Cirrhosis: A Placebo-Controlled, Double-Blind Study","volume":"103","author":"Schepke","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/gast.2001.26295","article-title":"Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension","volume":"121","author":"Schepke","year":"2001","journal-title":"Gastroenterology"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Klein, S., Herath, C.B., Schierwagen, R., Grace, J., Haltenhof, T., Uschner, F.E., Strassburg, C.P., Sauerbruch, T., Walther, T., and Angus, P.W. (2015). Hemodynamic Effects of the Non-Peptidic Angiotensin-(1\u20137) Agonist AVE0991 in Liver Cirrhosis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0138732"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jhep.2005.04.017","article-title":"Neutral endopeptidase (EC 3.4.24.11) in cirrhotic liver: A new target to treat portal hypertension?","volume":"43","author":"Aragno","year":"2005","journal-title":"J. Hepatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/4\/702\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:22:47Z","timestamp":1760160167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/4\/702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,11]]},"references-count":127,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["jcm10040702"],"URL":"https:\/\/doi.org\/10.3390\/jcm10040702","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,11]]}}}